Semaglutide
GLP-1 Receptor Agonist — Ozempic® (Diabetes) / Wegovy® (Weight Loss)
Overview & Background
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It was first approved by the FDA in 2017 under the brand name Ozempic® for the treatment of type 2 diabetes mellitus, and subsequently approved in 2021 as Wegovy® at a higher dose (2.4mg weekly) specifically for chronic weight management. It also exists as an oral formulation — Rybelsus® — approved for type 2 diabetes. The compound rapidly became one of the most prescribed medications in the United States, fundamentally reshaping the treatment landscape for both metabolic disease and obesity.
The molecule itself is a synthetic analog of human GLP-1, sharing approximately 94% structural homology with the native hormone. Its extended half-life — enabling once-weekly dosing — is achieved through a C-18 fatty diacid chain attached to the peptide backbone via a linker, which allows it to bind reversibly to serum albumin. This albumin binding protects the molecule from rapid enzymatic degradation and renal clearance, dramatically extending its duration of action compared to native GLP-1 (which has a half-life of only 1–2 minutes).
Beyond its approved indications, semaglutide has become one of the most clinically studied compounds in metabolic medicine, with ongoing or completed trials examining its role in cardiovascular disease (the SELECT trial showing 20% reduction in MACE), chronic kidney disease, non-alcoholic steatohepatitis, Alzheimer's disease, addiction, and polycystic ovarian syndrome. Its broad utility in metabolic conditions has made it a cornerstone compound in the emerging field of GLP-1 based therapeutics.
Clinical Research & Evidence
The evidence base for semaglutide is among the most robust of any metabolic pharmaceutical. The SUSTAIN trial program (8 trials) established its efficacy and safety in type 2 diabetes, demonstrating HbA1c reductions of 1.0–1.8% and significant cardiovascular risk reduction (SUSTAIN-6). The STEP trial program (5 trials) established its weight loss efficacy: at 2.4mg weekly over 68 weeks, participants achieved a mean weight loss of 14.9% compared to 2.4% for placebo — approximately 35 pounds for an average participant. Nearly 33% of participants lost more than 20% of body weight.
The SELECT cardiovascular outcomes trial, published in 2023, was a landmark study enrolling 17,604 adults with obesity and established cardiovascular disease (but without diabetes). It demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — with semaglutide 2.4mg compared to placebo. This was the first demonstration that a weight loss medication reduces hard cardiovascular endpoints, effectively reframing obesity treatment as cardiovascular medicine.
Additional significant findings include: reduction in liver fat content and liver enzyme normalization in patients with NAFLD/NASH (ESSENCE trial), improvement in sleep apnea severity (SURMOUNT-OSA equivalent), and reductions in kidney disease progression markers. The oral formulation (Rybelsus) demonstrated meaningful HbA1c reduction in the PIONEER trial program, expanding access for patients who cannot or prefer not to self-inject.
Reported Benefits
Weight loss is the most sought-after benefit of semaglutide in the current clinical and consumer landscape. The 15% average body weight reduction achieved at the 2.4mg dose represents a meaningful inflection point — a threshold above which substantial co-morbidity improvement (joint pain, sleep apnea, hypertension, dyslipidemia) consistently occurs. For many patients, this degree of weight loss produces improvements in quality of life that rival surgical interventions, without the risks associated with bariatric surgery.
Glycemic control is the original and still highly relevant benefit. For patients with type 2 diabetes, semaglutide reduces fasting and postprandial glucose, lowers HbA1c, and does so through a glucose-dependent mechanism that minimizes hypoglycemia risk — a significant advantage over insulin and sulfonylureas. The weight loss that accompanies treatment often leads to further glycemic improvement and, in some cases, remission of type 2 diabetes in patients with shorter disease duration.
Emerging research suggests semaglutide may also reduce addictive behaviors — including alcohol consumption, smoking, and compulsive eating — through central nervous system effects on reward pathways. This "food noise" reduction (diminished intrusive thoughts about food) is consistently reported by patients and may represent a distinct mechanism of action separate from simple appetite suppression. Research into semaglutide's neurological effects is an active and rapidly expanding area of investigation.
Dosing Protocols
For injectable semaglutide (Ozempic or Wegovy), the standard titration protocol for weight management begins at 0.25mg once weekly for 4 weeks, then 0.5mg for 4 weeks, then 1.0mg for 4 weeks, then 1.7mg for 4 weeks, reaching the target maintenance dose of 2.4mg weekly at week 16–20. This slow titration is essential to allow the gastrointestinal tract to adapt and minimize nausea and vomiting. Some patients remain at intermediate doses (0.5mg or 1.0mg) due to tolerability issues and can still achieve meaningful clinical benefit.
For diabetes management with Ozempic, the target dose is typically 0.5mg or 1.0mg weekly, with 2.0mg available for patients requiring additional glycemic control. For oral semaglutide (Rybelsus), the starting dose is 3mg daily for 30 days, then 7mg daily for 30 days, then 14mg daily. The oral formulation has lower bioavailability (~1%) than the injectable and must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating or drinking anything else.
Compounded semaglutide (available through licensed compounding pharmacies during periods of shortage) typically uses the same dose and titration schedule. Important caveat: compounded formulations may have different excipients, concentrations, and quality controls compared to branded products, and patients should ensure their compounding pharmacy is PCAB-accredited or operates under strict quality standards. The FDA has periodically issued guidance on the status of compounded semaglutide availability.
Reconstitution Guide
FDA-approved branded semaglutide (Ozempic, Wegovy) comes pre-filled in a multi-dose pen that requires no reconstitution. The pen is pre-primed, dose-calibrated, and ready for use after attaching a new needle. Each pen contains multiple doses at the appropriate concentration for the prescribed dose level. The pens should never be shaken, frozen, or exposed to heat or direct sunlight.
For compounded semaglutide supplied as a lyophilized powder, reconstitution follows standard peptide protocols: add sterile bacteriostatic water slowly to the vial targeting a concentration of typically 1–5mg/mL, gently swirl to dissolve without shaking, verify the solution is clear and colorless before use. Accurate concentration calculation is critical — errors here propagate directly to dosing errors. Always double-check volume calculations with your prescribing provider.
Some compounding pharmacies supply semaglutide as a pre-mixed solution ready for injection, eliminating the reconstitution step. In this format, the solution arrives in vials or syringes at a stated concentration, and the patient draws the appropriate volume per their dose. Regardless of format, verify expiration dates, inspect for particulates or discoloration, and maintain cold-chain storage throughout.
Half-Life & Pharmacokinetics
Semaglutide has a half-life of approximately 7 days, which is the pharmacokinetic basis for its once-weekly dosing. This extended half-life is achieved through albumin binding via the fatty acid chain modification, combined with resistance to dipeptidyl peptidase-4 (DPP-4) enzyme degradation due to an amino acid substitution at position 8 of the GLP-1 sequence. The result is a molecule that circulates for weeks rather than the minutes characteristic of native GLP-1.
After subcutaneous injection, semaglutide reaches peak plasma concentrations (Tmax) at approximately 24–72 hours. Steady-state concentrations are achieved after 4–5 weeks of weekly dosing. The drug is distributed throughout the body with a volume of distribution of approximately 12.5 liters, indicating primarily vascular and extravascular distribution rather than extensive tissue penetration. Metabolism occurs through proteolytic cleavage and beta-oxidation of the fatty acid chain, with excretion split between urine and feces.
The 7-day half-life has practical implications: if semaglutide is discontinued, the drug takes approximately 5 weeks to be substantially cleared from the body. During this washout period, appetite typically returns and weight regain can begin. This pharmacokinetic reality underlies the clinical observation that semaglutide works while it is taken — and weight tends to return when it is stopped — emphasizing the importance of long-term treatment planning.
Administration Methods
Injectable semaglutide is administered subcutaneously once weekly. Injection sites include the abdomen (periumbilical area, avoiding 2 inches around the navel), upper thigh, and upper arm. Site rotation is essential. The Ozempic and Wegovy pens come with disposable needles (NovoFine or equivalent) of 4mm or 8mm length — shorter needles (4mm) are preferred for most patients and can be inserted perpendicularly (90 degrees) without pinching. Longer needles may require a 45-degree angle in thinner patients to avoid intramuscular injection.
Oral semaglutide (Rybelsus) is administered as a tablet once daily. The strict dosing requirements — empty stomach, minimal water, 30-minute wait — are non-negotiable for adequate absorption. The oral bioavailability of semaglutide is only approximately 1% under optimal conditions and drops further if these conditions are not met. Patients who drink coffee, eat, or take other medications within the 30-minute window will have significantly reduced drug absorption.
The day of the week for subcutaneous injection can be changed if needed, provided at least 48 hours separate the old and new injection days. Semaglutide can be administered at any time of day, with or without food — unlike the oral version. Most patients develop a routine of a specific day and time that fits their lifestyle, which improves adherence. Setting a weekly reminder is strongly recommended to prevent missed doses.
Side Effects & Contraindications
Gastrointestinal side effects are the most common adverse events with semaglutide, occurring in a majority of patients at some point during treatment. Nausea is most prevalent (reported in 44% of STEP trial participants at 2.4mg vs 16% for placebo), followed by diarrhea, vomiting, constipation, and abdominal discomfort. These effects are most intense during the titration phase and in the first 4–12 weeks of a new dose level. For most patients, symptoms are manageable and resolve over time. Dietary adjustments — smaller portions, lower-fat foods, slower eating — significantly reduce severity.
Rarer but more serious adverse events include acute pancreatitis (incidence appears low but patients should be counseled to report severe abdominal pain), gallbladder disease and cholelithiasis (gallstone formation, with an approximately 2-fold increased risk compared to placebo in weight loss trials — likely related to rapid weight loss itself), and heart rate increases of 1–4 beats per minute. Acute kidney injury, typically related to dehydration from GI fluid losses, has been reported and underscores the importance of adequate hydration.
Contraindications include: personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (GLP-1 receptor agonist class warning based on rodent carcinogenicity data), known hypersensitivity to semaglutide, pregnancy and breastfeeding (insufficient safety data; women of childbearing potential should use effective contraception and discontinue at least 2 months before planned pregnancy), and severe gastroparesis. Caution is warranted in patients with a history of diabetic retinopathy — rapid glycemic improvement has been associated with worsening of pre-existing retinopathy in some patients.
Stacking Protocols
Semaglutide should not be combined with other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide) or with tirzepatide, as these combinations provide no additional benefit while increasing side effect burden and cost. The exception in research settings is the investigation of semaglutide combined with complementary mechanisms — such as amylin analogs (cagrilintide) — which is being evaluated in the REDEFINE trial program under the combination product called CagriSema. This combination has shown additive weight loss beyond semaglutide alone.
For individuals using semaglutide in the context of broader wellness or performance protocols, common co-interventions include: growth hormone secretagogues (MK-677, CJC-1295/ipamorelin) to help preserve lean muscle mass during weight loss; metformin for additional metabolic support and potential longevity benefits; berberine as an adjunct to glycemic management; and NAD+ precursors (NMN, NR) for mitochondrial support during the metabolic transition. These combinations are not standard of care and lack clinical trial validation.
Patients on insulin or sulfonylureas who add semaglutide require close monitoring and typically need dose reductions in their existing diabetes medications to prevent hypoglycemia. The combination of semaglutide with metformin is generally well-tolerated and is a common first combination in type 2 diabetes management. All medication combinations should be reviewed and approved by a prescribing physician who has access to the patient's complete medication list and medical history.
Storage & Stability
Branded Ozempic and Wegovy pens should be stored in the refrigerator (2–8°C) before first use. Once in use, the pen can be kept at room temperature (below 30°C/86°F) for up to 56 days for Ozempic, or 28 days for Wegovy. Do not freeze semaglutide pens — frozen medication must be discarded. Keep the pen cap on when not in use and store away from heat and direct light. The needle should be removed and discarded after each injection; never store the pen with a needle attached.
Compounded semaglutide solutions should be stored refrigerated throughout their shelf life, which is typically 28–90 days depending on the formulation and preservatives used. Bacteriostatic water (with benzyl alcohol) extends stability compared to sterile water. Inspect before each use — discard if the solution appears cloudy, discolored, or contains particulates. Once removed from the refrigerator, allow to reach room temperature naturally before injection to minimize injection site discomfort.
For travel, branded pens and compounded vials should be kept in an insulated cooler with ice packs (not directly on ice) to maintain the 2–8°C cold chain. Most international airlines and TSA allow injectable medications in carry-on luggage. Carry a physician letter or prescription documentation for security and customs purposes. Avoid checking injectable medications in luggage that may be exposed to extreme temperatures in cargo holds.
Legal Status & Availability
Semaglutide has full FDA approval in the United States: Ozempic® (0.5mg, 1mg, 2mg weekly) for type 2 diabetes; Wegovy® (2.4mg weekly) for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity; Rybelsus® (3mg, 7mg, 14mg daily oral) for type 2 diabetes. It is also approved in the EU (Ozempic, Wegovy, Rybelsus), Canada, Australia, Japan, and most major markets. It is available by prescription only.
Due to unprecedented demand, semaglutide experienced significant supply shortages beginning in 2022. The FDA placed Ozempic and Wegovy on the drug shortage list, which created a legal framework for compounding pharmacies to produce semaglutide under the federal drug shortage exemption. As supply has improved, the FDA has indicated it may remove semaglutide from the shortage list, which would restrict compounded availability. Patients relying on compounded semaglutide should follow regulatory developments closely.
Insurance coverage for Wegovy (weight loss indication) remains highly variable. Many commercial insurance plans cover Ozempic for diabetes but exclude Wegovy for obesity, citing cost concerns. Medicare did not cover anti-obesity medications until recently. GoodRx and manufacturer patient assistance programs can significantly reduce out-of-pocket costs. Patients without insurance coverage should explore all available programs before assuming the medication is unaffordable — list prices do not reflect actual patient costs in many cases.
Bloodwork & Monitoring
Baseline laboratory evaluation before initiating semaglutide should include: HbA1c and fasting glucose (glycemic baseline), comprehensive metabolic panel (kidney and liver function), fasting lipid panel (triglycerides, HDL, LDL, total cholesterol), TSH (thyroid function), amylase and lipase (pancreatic baseline), and a complete blood count. For patients with existing diabetes, more frequent initial glucose monitoring may be indicated, particularly if they are on insulin or sulfonylureas.
Follow-up monitoring at 3 months should assess HbA1c response (expect 0.5–1.5% reduction depending on baseline), weight and BMI, blood pressure, and kidney function (eGFR, creatinine) — particularly in patients with pre-existing CKD or those experiencing significant fluid losses from GI side effects. Liver enzymes should be checked if baseline values were elevated or if the patient develops abdominal symptoms. Repeat lipid panel at 6 months to assess cardiovascular risk factor modification.
Patients with pre-existing diabetic retinopathy require ophthalmological evaluation before initiating semaglutide and monitoring during the period of rapid glycemic improvement, as the sudden normalization of blood glucose can paradoxically worsen retinopathy in some cases. Bone density monitoring (DEXA) is reasonable for patients losing large amounts of weight (>15% body weight), as significant weight loss can be associated with bone mineral density reduction, partially offset by resistance exercise. Annual comprehensive metabolic panels are appropriate for long-term maintenance therapy.
Track Semaglutide with Dosi
Log doses, track your titration, and monitor progress with AI-powered guidance. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before using any compound.